Opus Genetics, Inc. Long-Term Debt
Opus Genetics, Inc. (IRD) had Long-Term Debt of $1.20 million as of 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:LongTermDebtNoncurrent · last filed 2026-05-12
- 2026-03-31: Long-term Debt, Excluding Current Maturities $1.20M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $1.13M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $1.07M.
- 2025-06-30: Long-term Debt, Excluding Current Maturities $1.00M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.13M 10-Q · filed 2026-05-12 |
| 2025-09-30 | $1.07M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.00M 10-Q · filed 2025-08-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |